221At-and 131I-labeled bisphosphonates with high in vivo stability and bone accumulation

RH Larsen, KM Murud, G Akabani… - The Journal of Nuclear …, 1999 - search.proquest.com
211At— and 131l—Labeled Bisphosphonates with High Page 1 211At— and 131l—Labeled
Bisphosphonates with High In Vivo Stability and Bone Accumulation Roy H. Larsen, Kristin M …

188Re-labeled bisphosphonates as potential bifunctional agents for therapy in patients with bone metastases

A El-Mabhouh, JR Mercer - Applied radiation and isotopes, 2005 - Elsevier
Two new bisphosphonates have been examined for their ability to bind 188Re and deliver it
selectively to bone. The bisphosphonates are prototype compounds with potential to deliver …

Synthesis, purification, and in vitro stability of 211At-and 125I-labeled amidobisphosphonates

KM Murud, RH Larsen, P Hoff, MR Zalutsky - Nuclear medicine and biology, 1999 - Elsevier
A method is described for preparing 211At-and radioiodinated amidobisphosphonates. The
active esters N-succinimidyl 3-(tri-methylstannyl) benzoate (ATE) and N-succinimidyl 5-(tri …

[PDF][PDF] Indium-113m-labeled polyfunctional phosphonates as bone-imaging agents

G Subramanian, JG McAfee… - Journal of Nuclear …, 1975 - Soc Nuclear Med
MATERIALS AND METHODS Ethylenediaminetetra(methylene phosphonic) acid (an analog
of EDTA, herein called EDTMP), hexamethylenediaminetetra (methylene phosphonic) acid …

Studies on the Synthesis and Biological Properties of Non-Carrier-Added [125I and 131I]-Labeled Arylalkylidenebisphosphonates:  Potent Bone-Seekers for …

E Årstad, P Hoff, L Skattebøl, A Skretting… - Journal of medicinal …, 2003 - ACS Publications
Arylalkylidenebisphosphonates labeled with nca [125I or 131I] have been synthesized and
their biological function investigated. The label was attached to the aromatic group in high …

Pharmaco-kinetics of current skeletal-seeking radiopharmaceuticals

GT Krishnamurthy, RJ Huebotter… - American Journal of …, 1976 - Am Roentgen Ray Soc
The blood clearance of all current bone-seeking radiopharmaceuticals is biexponential
during the first four hours after injection. Exponent I represents bone uptake and its …

Bone seeking radiopharmaceuticals

CL De Ligny, WJ Gelsema, TG Tji, YM Huigen… - International journal of …, 1990 - Elsevier
A comprehensive review on technetium chemistry and technetium radiopharmaceuticals
was published by Deutsch et al.(1983) and the chemistry of technetium in its IV states was …

Design of a radiopharmaceutical for the palliation of painful bone metastases: rhenium‐186‐labeled bisphosphonate derivative

K Ogawa, T Mukai, Y Arano, H Hanaoka… - Journal of Labelled …, 2004 - Wiley Online Library
To develop a radiopharmaceutical for the palliation of painful bone metastases based on the
concept of bifunctional radiopharmaceuticals, we designed a bisphosphonate derivative …

New bone-seeking agent: Animal study of Tc-99m-incadronate

M Shigematsu, S Shiomi, H Iwao, H Ochi - Annals of nuclear medicine, 2002 - Springer
Objective: Disodium cycloheptylaminomethylenediphosphonate monohydrate (incadronate
disodium) is a third-generation bisphosphonate compound which potently inhibits bone …

Rhemium-186-monoaminemonoamidedithiol-conjugated bisphosphonate derivatives for bone pain palliation

K Ogawa, T Mukai, Y Arano, A Otaka, M Ueda… - Nuclear medicine and …, 2006 - Elsevier
To develop a radiopharmaceutical for the palliation of painful bone metastases based on the
concept of bifunctional radiopharmaceuticals, we synthesized a bisphosphonate derivative …